AJM300

an alpha4 integrin antagonist

Also Known As:

L-phenylalanine, N-(2,6-dichlorobenzoyl)-4-(6-(dimethylamino)-1,4-dihydro-1-methyl-2,4-dioxo-3(2H)-quinazolinyl)-, methyl ester; carotegrast methyl; methyl N-(2,6-dichlorobenzoyl)-4-(6-(dimethylamino)-1-methyl-2,4-dioxo-1,4-dihydro-3(2H)-quinazolinyl)-L-phenylalaninate

Networked: 13 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kajioka, Toshifumi: 3 articles (01/2022 - 01/2020)
2.	AJM300 Study Group: 2 articles (01/2022 - 12/2015)
3.	Hibi, Toshifumi: 2 articles (01/2022 - 12/2015)
4.	Matsuoka, Katsuyoshi: 2 articles (01/2022 - 12/2015)
5.	Watanabe, Kenji: 2 articles (01/2022 - 12/2015)
6.	Watanabe, Mamoru: 2 articles (01/2022 - 12/2015)
7.	Fukase, Hiroyuki: 2 articles (03/2020 - 01/2020)
8.	Furuie, Hidetoshi: 2 articles (03/2020 - 01/2020)
9.	Ikeda, Naoki: 2 articles (03/2020 - 01/2020)
10.	Oikawa, Ichiro: 2 articles (03/2020 - 01/2020)

Related Diseases

1.	Ulcerative Colitis 12/01/2015 - "We performed a randomized trial to investigate the efficacy and safety of AJM300 in patients with active ulcerative colitis (UC). " 01/01/2023 - "Carotegrast methyl can be a treatment option that meets that unmet medical need and has the potential to greatly contribute to the treatment of ulcerative colitis based on the thorough practice of proper use. " 01/01/2023 - "and Kissei Pharmaceutical Co., Ltd., the efficacy and safety of carotegrast methyl were confirmed in patients with moderate active ulcerative colitis. " 06/01/2022 - "This article summarizes the milestones in the development of carotegrast methyl leading to this first approval for the treatment of moderate ulcerative colitis." 01/01/2022 - "We assessed the efficacy and safety of AJM300 in patients with moderately active ulcerative colitis. "
2.	Hemorrhage 12/01/2015 - "In a double-blind, placebo-controlled, phase 2a study, 102 patients with moderately active UC (Mayo Clinic scores of 6-10, endoscopic subscores ≥2, and rectal bleeding subscores ≥1) who had inadequate response or intolerance to mesalamine or corticosteroids were randomly assigned to receive AJM300 (960 mg) or placebo 3 times daily for 8 weeks. "
3.	Abscess 01/01/2022 - "A serious adverse event was reported in the AJM300 group (one patient with anal abscess), but this was judged to be unrelated to study drug. "
4.	Colitis 12/01/2013 - "AJM300 dose-dependently prevented the development of experimental colitis in mice. " 12/01/2013 - "Oral treatment with the selective small molecule α4 integrin antagonist (AJM300) prevented the development of colitis and its efficacy was comparable to that of the anti-α4 integrin antibody." 12/01/2013 - "Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice." 09/01/2012 - "Notice of withdrawal: A novel, orally active alpha 4 integrin antagonist, AJM300 prevents the development of experimental colitis induced by adoptive transfer of IL-10 deficient CD4+ T cells in mice." 07/03/2012 - "A novel, orally active alpha 4 integrin antagonist, AJM300 prevents the development of experimental colitis induced by adoptive transfer of IL-10 deficient CD4(+) T cells in mice."
5.	Inflammation (Inflammations) 01/01/2020 - "AJM300 is an oral antagonist of α4-integrin that reduces inflammation by blocking leucocyte trafficking. " 06/01/2016 - "This review discusses the current approaches with promising new oral drugs with distinct modes of action, including: the Janus kinase inhibitors (i.e., tofacitinib, filgotinib and peficitinib); the immunomodulatory drug (laquinimod); a small α4 antagonist (AJM300); agonists for sphingosine-phosphate receptors (i.e., ozanimod, APD334, and amiselimod), as well as anti-sense therapy (mongersen) targeting SMAD7, drugs which directly target intracellular pathways of relevance for intestinal inflammation. "

Related Drugs and Biologics

1.	Integrins
2.	AJM300
3.	Mesalamine (Mesalazine)
4.	tofacitinib
5.	Adrenal Cortex Hormones (Corticosteroids)
6.	upadacitinib
7.	Interleukin-10 (Interleukin 10)
8.	ozanimod
9.	Sphingosine
10.	Prodrugs

Related Therapies and Procedures

1.	Therapeutics